Recent

% | $
Quotes you view appear here for quick access.

Santarus, AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • watchthedownside watchthedownside Sep 9, 2010 8:19 AM Flag

    From 5/2009 to now, no one wanted this?

    $200mm potential revenue that will only yield $20mm in net income at best.....matters a ton to SNTS at current stock price, but not sure it mattered enough to larger pharma...in fact, probably makes this a $4 or $5 stock vs. a $2 stock

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • After Zegerid, this makes perfect sense. It fits well with Glumetza. It may do unexpectedly well, but even if it doesn't catch on, I doubt if it will be a complete bomb, since it does drop A1c a bit. Also the climate for a heart safe drug (and probably tho unclaimably heart protective) is probably better than it was a year ago.

 
SNTS
0.00(0.00%)